Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.76 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.72 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.72 |
| ▸ | ENPP2 | Q13822 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.63 |
| ▸ | SELP | P16109 | 1/20 | 0.60 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503997 | 0.99 | FABP3 (0.78) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL15386588 | 0.91 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL12236914 | 0.91 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL10033710 | 0.91 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL8738898 | 0.91 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL12648548 | 0.91 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL19821350 | 0.91 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL15120601 | 0.91 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL14793212 | 0.91 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL14793208 | 0.91 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | claimed |
| EP-2410991-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (an Ohio Corporation ) (US) | 2012-02-01 | — | — | EP | claimed |
| WO-2010111271-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (AN OHIO CORPORATION) (US) | 2010-09-30 | — | — | WO | claimed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | claimed |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10577554-B2 | Gas-filled stabilized particles and methods of use | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-03-03 | — | — | US | disclosed |
| US-20160030596-A1 | GAS-FILLED STABILIZED PARTICLES AND METHODS OF USE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160030596-A1 | GAS-FILLED STABILIZED PARTICLES AND METHODS OF USE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2016-02-04 | — | — | US | disclosed |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2410991-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (an Ohio Corporation ) (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111271-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (AN OHIO CORPORATION) (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | FABP3 7/4885LPAR3 1320/4885LPAR1 896/4885 |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | FABP3 7/4885LPAR3 1320/4885LPAR1 896/4885 |
| US-20160030596-A1 | GAS-FILLED STABILIZED PARTICLES AND METHODS OF USE | LIPA, PPARG, LPXN | FABP3 804/4885LPAR3 755/4885LPAR1 442/4885 |
| US-10577554-B2 | Gas-filled stabilized particles and methods of use | LIPA, PPARG, LPXN | FABP3 804/4885LPAR3 755/4885LPAR1 442/4885 |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | FABP3 5/4885LPAR3 1396/4885LPAR1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.